.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Fuji
Baxter
Covington
Dow
Deloitte
Daiichi Sankyo
Boehringer Ingelheim
Mallinckrodt
AstraZeneca

Generated: September 22, 2017

DrugPatentWatch Database Preview

AMRIX Drug Profile

« Back to Dashboard

What is the patent landscape for Amrix, and when can generic versions of Amrix launch?

Amrix is a drug marketed by Teva Pharms Intl and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one patent family member in one country.

The generic ingredient in AMRIX is cyclobenzaprine hydrochloride. There are fifteen drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the cyclobenzaprine hydrochloride profile page.

Summary for Tradename: AMRIX

Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: see list7
Bulk Api Vendors: see list51
Clinical Trials: see list2
Patent Applications: see list690
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:AMRIX at DailyMed

Pharmacology for Tradename: AMRIX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-001Feb 1, 2007RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-001Feb 1, 2007RXYesNo► Subscribe► Subscribe ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-001Feb 1, 2007RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-002Feb 1, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-002Feb 1, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-002Feb 1, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-001Feb 1, 2007RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-001Feb 1, 2007RXYesNo► Subscribe► SubscribeY ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-001Feb 1, 2007RXYesNo► Subscribe► Subscribe ► Subscribe
Teva Pharms Intl
AMRIX
cyclobenzaprine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021777-001Feb 1, 2007RXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: AMRIX

Drugname Dosage Strength RLD Submissiondate
cyclobenzaprine hydrochlorideExtended-release Capsule15 mg and 30 mgAmrix8/11/2008

Non-Orange Book Patents for Tradename: AMRIX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,877,245Modified release dosage forms of skeletal muscle relaxants► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: AMRIX

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2005048996► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
QuintilesIMS
UBS
Federal Trade Commission
US Army
Fuji
McKesson
Moodys
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot